Table 1.
Characteristics of Randomized Studies Evaluating the Efficacy of Nirmatrelvir/Ritonavir or Molnupiravir in Patients With Coronavirus Disease 2019 and Long COVID
| Characteristic | No Published Dataa | Published Data |
|---|---|---|
| No. of trials | 9 | 14 |
| Drug, No. (%) | ||
| Molnupiravir | 2 (22.2) | 8 (57.1) |
| Nirmatrelvir/ritonavir | 7 (77.8) | 4 (28.6) |
| Both | 0 (0.0) | 2 (14.3) |
| Phase, No. (%) | ||
| 1 | 0 (0.0) | 1 (7.1) |
| 2 | 4 (44.4) | 3 (21.4) |
| 2/3 | 0 (0.0) | 4 (28.6) |
| 3 | 5 (55.6) | 3 (21.4) |
| 4 | 0 (0.0) | 1 (7.1) |
| NI | 0 (0.0) | 2 (14.3) |
| Blind, No. (%) | ||
| Blind | 6 (66.7) | 6 (42.9) |
| NI | 0 (0.0) | 1 (7.1) |
| Open | 3 (33.3) | 7 (50.0) |
| No. of participants, median (IQR) | … | 278 (152–1130) |
| Predominant variant, No. (%) | ||
| Alpha | 0 (0.0) | 2 (14.3) |
| Delta | 0 (0.0) | 4 (28.6) |
| Delta/Omicron | 0 (0.0) | 1 (7.1) |
| NI | 8 (88.9) | 0 (0.0) |
| Omicron | 1 (11.1) | 7 (50.0) |
| Country, No. (%) | ||
| Belgium | 0 (0.0) | 1 (7.1) |
| Canada | 1 (11.1) | 0 (0.0) |
| China | 0 (0.0) | 3 (21.4) |
| India | 0 (0.0) | 1 (7.1) |
| Multiple | 0 (0.0) | 5 (35.7) |
| Norway | 1 (11.1) | 0 (0.0) |
| Russia | 2 (22.2) | 0 (0.0) |
| South Africa | 1 (11.1) | 0 (0.0) |
| Sweden | 1 (11.1) | 0 (0.0) |
| Thailand | 0 (0.0) | 1 (7.1) |
| United Kingdom | 0 (0.0) | 2 (14.3) |
| United States | 3 (33.3) | 1 (7.1) |
| Percentage vaccinated, median (IQR) | … | 67.0 (0–92) |
| Primary outcome, No. (%) | ||
| Death | 0 (0.0) | 2 (14.3) |
| Hospitalization | 0 (0.0) | 1 (7.1) |
| Hospitalization/death | 2 (22.2) | 4 (28.6) |
| Quality of life | 1 (11.1) | 0 (0.0) |
| Symptoms | 6 (66.7) | 2 (14.3) |
| Viral clearance | 0 (0.0) | 5 (35.7) |
| Status on ClincialTrials.gov, No. (%) | ||
| Completed | 3 (33.3) | 3 (21.4) |
| Ongoing | 6 (66.7) | 8 (57.1) |
| Terminated | 0 (0.0) | 3 (21.4) |
Abbreviations: IQR, interquartile range; NI, not indicated.
aData were considered unpublished if we were unable to find any peer-reviewed publications, preprints, or conference abstracts reporting trial results, or if there were no results published on ClinicalTrials.gov.